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Abstract 
 
Colitis can be a life-threatening immune-related adverse event (irAE) for patients with 
metastatic melanoma treated with immune checkpoint blockade, a new anti-cancer 
immunotherapy. With the increasing use of PD-1/PD-L1 and CTLA-4 inhibitors, 
particularly in combination in melanoma and other cancers, timely and accurate diagnosis 
of colitis will become increasingly important for oncologists.  The main goal of this study 
is to understand the clinical presentation of ipilimumab-induced colitis and to validate the 
use of CT scans as a safe and effective diagnostic tool. We analyzed a cohort of 303 
patients who received ipilimumab at Dana Farber Cancer Institute on an expanded access 
protocol or standard of care between the years of 2008 and 2015. Age, number of doses 
and frequency of ipilimumab doses were found to be clinical characteristics which could 
help differentiate patients who develop ipilimumab induced colitis from those who only 
present with diarrhea and other gastrointestinal symptoms. Of the 303 patients, 100 
(33%) developed diarrhea and 43 (14%) received treatment with corticosteroids for 
ipilimumab-induced colitis. For all patients with suspected immune-related colitis, an 
effort was made to firmly establish the diagnosis prior to or immediately after initiation 
of treatment. Forty-one of 43 patients (95%) who received steroids for presumed 
immune-related colitis had a colonoscopy and 27 of 43 (63%) patients had both 
	  v 
computed tomography (CT) of the abdomen/pelvis and a colonoscopy including biopsy.  
In the 31 patients with a CT and biopsy, CT was highly predictive of the presence of 
colitis on biopsy (sensitivity 85%, specificity 75%, PPV 96%) and the absence of CT 
findings was predictive of a negative biopsy (negative LR 0.2). In the 44 patients who 
had symptoms and CT evaluation, CT was highly predictive of the need for steroids to 
reach resolution of symptoms (sensitivity 85%, specificity 88%, PPV 92%, positive LR 
7.3). Fifteen of the 17 patients with negative CT findings did not require steroids to reach 
resolution of symptoms. In conclusion, CT of the abdomen/pelvis is a fast, reliable, and 
non-invasive mode of diagnosing ipilimumab-induced immune-related colitis, whereas 
colonoscopy may not be needed to firmly establish that diagnosis.  
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INTRODUCTION 
 
Melanoma is the deadliest form of skin cancer and its incidence is rising faster 
than any other solid tumor1. In the United States, there were 76,000 new cases in 2014 
and approximately 10,000 deaths1. Melanoma develops by malignant transformation of 
melanocytes, which are cells that make the pigment melanin and are typically associated 
with the skin but can occur on the eyes, ears, meninges, bone, heart and intestines1,2.  The 
greatest risk of developing melanoma comes from UVA and UVB exposure from the sun 
or tanning beds. However, genetics also play a role. Lighter skinned people have higher 
rates of melanoma; non-Hispanic whites are more likely to develop melanoma than those 
of other races. Melanoma also disproportionately affects men over women and can occur 
at a wide spectrum of ages. Thickness, ulceration status of the primary skin tumor and the 
presence or absence of regional lymph node or distant metastases are the major elements 
of staging and determine the prognosis of melanoma1. 
Melanoma accounts for 75% of skin cancer deaths. Prevention and early diagnosis 
are still the best treatments for melanoma and, until 2010, distant metastatic melanoma 
(AJCC stage IV) had a median survival of 6–12 months compared with early Stage 1 
melanoma which has a 3-year survival rate of 90%. Before the advent of the anti-CTLA-
4 monoclonal antibody ipilimumab, dacarbazine, a single agent chemotherapy approved 
by the FDA in 1975, was the first line treatment for patients with metastatic melanoma3. 
Dacarbazine has a response rate of 6–15% and only 2% of patients treated with 
dacarbazine were alive 6 years after treatment2,4. The overall 10 year survival rate of 
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patients with metastatic melanoma was 10% in 20093.   
 In 2010, ipilimumab was the first treatment to show improvement in overall 
survival for metastatic melanoma. Inhibitory checkpoint signals expressed on T cells and 
other immune cells modulate the immune response after initial activation to prevent 
damage to healthy self tissues 5. The cytotoxic T-lymphocyte associated antigen 4 
(CTLA-4) and programed cell death protein 1 (PD-1) are examples of immune check 
points. CTLA-4 acts during the activation of T-cells in the lymph node, while the role of 
PD-1 is to shut down already activated T-cells in peripheral tissues (further detail below). 
Immune checkpoint inhibitors are antibody treatments that reduce the ability of specific 
immune cells to produce inhibitory signals and thus produce a greater immune response 
to low stimulatory antigens and antigens present in immune suppressive environments. In 
simpler terms, immune checkpoint inhibitors are a type of cancer treatment which can 
reactivate attenuated immune cells, increasing the potential for an immune reaction 
against the cancer5.  
Ipilimumab was the first immune check point inhibitor approved by the FDA 
(2011) and until recently was the only therapy with improved overall survival for 
metastatic melanoma. Ipilimumab is an an antibody against CTLA-4 which binds to 
CTLA-4 and prevents its binding to the ligand CD80/86 as well as preventing the 
inhibition of T-cell activation. Ipilimumab has a response rate of 10 to 15% and a long 
term survival of 20% in advanced melanoma6,7,8. In 2014 two PD-1 immune checkpoint 
inhibitors were approved by the FDA: nivolumab and pembrolizumab4. These new 
therapies were associated with a 30 to 40% response rate in patients with metastatic 
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melanoma4. The immunological complementary functions of CTLA-4 and PD-1 have 
lead to clinical trials using combination of ipilimumab and nivolumab to treat metastatic 
melanoma, showing response rates of 54% in  patients with negative PDL-1 status, 
leading to FDA approval of this regimen in 20154,9,10. 
The blocking of inhibitory immune checkpoint signals also carries the risk of de-
regulating self-tolerance leading to immune related adverse events (irAE), which are 
different from those adverse events typically seen with chemotherapy11. Self-tolerance is 
the ability of the immune system to recognize and not attack the host’s cells. Immune 
checkpoints modulate the ability for the immune system to recognize self-cells and to 
turn off immune reactions when it encounters these cells. IrAE’s arise from the breaking 
of self-tolerance and thus mimic many known autoimmune diseases5. The irAE’s can 
include adverse gastrointestinal, dermatological, endocrine and hepatic events. 
Ipilimumab has been associated with several irAE’s due to the infiltration of normal 
tissues with active CD4 and CD8 T cells and inflammatory cytokines5,12. Most of the 
irAE’s are mild to moderate, affecting 70–88% of patients and some association between 
irAE’s and number of ipilimumab doses have been found but are not directly 
correlated6,13,14. Toxicities can occur at any point during therapy. Symptoms suggestive 
of irAE’s such as diarrhea and rash can have infectious or allergic etiologies, which 
should be ruled out prior to starting treatment with immunosuppressive agents, which 
could potentially counteract the treatment effect of immune checkpoint blockade. Given 
the potential life-threatening nature of some irAE’s, a timely and accurate diagnosis is 
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critical. Validating fast and non-invasive diagnostic tests to identify irAE’s is therefore 
desirable. 
Ipilimumab Mechanisms of Action  
The immune system has a dual function, which balances tumor surveillance and 
self-tolerance to identify and eliminate nascent tumors without causing damage to healthy 
tissues. Tumor surveillance is the continual process by which the immune system 
identifies and eliminates cancerous cells. The tumor surveillance process is hypothesized 
to happen continuously throughout life, eliminating many nascent cancers. This is a 
delicate balance since the immune system must be able to differentiate healthy self-cells 
from cancerous self-cells. Cancer cells can create environments which up-regulate self-
tolerance mechanisms to escape notice of the immune system.15,16. This immune 
suppressive environment can be complex and highly variable.  The tumor 
microenvironment can foster helper T cells which express the CTLA-4 receptor, creating 
a highly immune suppressive enviornement17,18,19.  CTLA-4 inhibits T-cell activation as 
part of the primary T cell activation cascade. For a T cell to recognize a tumor as 
‘foreign’ and become activated, two steps must occur. Firstly the T cell receptor (TCR) 
must bind with a tumor associated peptide bound to the MHC receptor of an antigen 
presenting cell (APC). After the coupling of the TCR with the potential tumor antigen it 
receives either a positive signal through the CD28 receptor or inhibitory signal through 
the CTLA-4 receptor.  Both receptors bind the same ligand (B7/CD80/CD86) however 
CTLA-4 binds B7/CD80/CD86 with greater affinity, skewing T cell activation towards 
tolerance15,16. The importance of CTLA-4 is highlighted by CTLA-4 knockout mice and	
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Figure 1: CTLA-4 Blockade with CTLA-4 Antibody 
 
CTLA-4 polymorphisms found in humans.  Complete blocking of CTLA-4 in murine 
models leads to massive lymph proliferation and death within 2–3 weeks of major organ 
failure due to lymphproliferative disease 20. No CTLA-4 negative phenotype exists in 
humans, however, studies in humans have shown that polymorphisms in CTLA-4 
receptors are linked to early onset type 1 diabetes, rheumatoid arthritis, autoimmune 
thyroid disease and endocrinopathies as well as Addison’s disease21,22,23,24.  Partially 
blocking CTLA-4 via an antibody, such as ipilimumab, which binds the CTLA-4 
receptor, blocks its ability to receive negative signals and allows for a greater number of 
T cells to become or stay activated via CD28 receptor binding. Using ipilimumab to 
partially block CTLA-4 enhances the endogenous immune response to induce tumor 
regression25. The partial blockade of this T cell inhibitor causes a large range of 
nonspecific off-target immune-based adverse events.,13,26. The triggers of the ipilimumab 
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induced irAE’s are unknown, but appear to be T cell mediated with characteristic T-cell-
rich tissues and inflammatory infiltrates without circulating antibodies. Therefore many 
of the irAEs mimic known autoimmune inflammatory conditions such as inflammatory 
bowel disease but show different etiologies which will be discussed later13.  
Ipilimumab Induced Colitis: Presentation, Identification and Treatment 
Ipilimumab associated gastrointestinal symptoms are the second most common 
reported irAE, with about 30–35% of patients having mild symptoms and 5–8% having 
moderate to severe symptoms6,26. Colitis, which is characterized as inflammation of the 
colon, can occur at any time during treatment, presentation can be subtle and other causes 
must be ruled out prior to treatment. Ipilimumab induced colitis can be severe and life-
threatening, especially if diagnosis is delayed. Most patients respond to treatment but 
some become refractory to treatment and have recurrence of symptoms with worsened 
severity13. 
 The primary symptom is diarrhea but can also include abdominal cramping, 
nausea, vomiting, GI bleeding, fever, fatigue, dyspepsia, leukocytosis, hypoalbuminemia, 
and serum electrolyte abnormalities27. In any patient receiving ipilimumab, the 
occurrence of diarrhea is concerning for immune related colitis. The timing of onset can 
vary even though it typically does not present until after the second dose13. Procedures 
have been developed for the identification and treatment for gastrointestinal adverse 
events28.  Firstly, other etiologies, such as other medication-induced diarrhea, infectious 
diarrhea, such as bacterial (Clostridium difficile) or viral infection (CMV colitis, 
particularly in cases of reoccurrence after prolonged steroids use) should be ruled out 
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through blood and stool studies. A flexible sigmoidoscopy or colonoscopy should be 
considered for persistent grade 2 diarrhea and any grade 3–4 diarrhea to rule out other 
diarrhea etiologies and confirm severity of colitis29,30,28.  During the workup to confirm 
ipilimumab-induced colitis, treatment should be held. Grade 1 and uncomplicated grade 2 
diarrhea are treated symptomatically and should be carefully monitored. If grade 2 
diarrhea persists, ipilimumab should be held and oral steroids should be administered. 
Patients with grade 3 or 4 diarrhea may need hospitalization during the workup with 
intravenous hydration, bowel rest, and high-dose IV steroids30. 	
 
Figure 2: irAE Gastrointestinal Management Algorithm 
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Monitoring of patients is critical as bowel perforations can develop28. For patients who 
have received maximal medical support and are refractory to steroid therapy, treatment 
with the TNF-alpha inhibitor infliximab should be considered. Partial or complete 
colectomy may be necessary as a last resort or if bowel perforation occurs30,28. Currently 
there are no markers to predict who will develop colitis, therefore monitoring and rapid 
identification of symptoms and administration of corticosteroids are key for an effective 
treatment strategy30.  
Mechanisms of Ipilimumab Induced Colitis 
The etiology of ipilimumab-induced colitis is believed to be the disruption of gut 
mucosal immunity. The complex intestinal mucosal immune system dynamically 
interacts with trillions of bacterial and food antigens. It has a dual purpose of protecting 
commensal bacteria and creating tolerance to food antigens while also mounting a strong 
inflammatory response to invading pathogens over a 400m2 area31. The gut immune 
system is comprised of lymphocytes, gut epithelium, connective tissue in the lamina 
propria, and Peyers patches (small lymphoid tissues). There are specialized subsets of T 
cells, which mediate different parts of immune response and tolerance. Broadly they are 
divided into two groups: killer or cytotoxic T- cells and T-helper cells. Generally the two 
sets of T cells are referred to by their co-receptor expression — cytotoxic T cells express 
the CD8 co-receptor and T helper cells express the CD4 co-receptor, hence T cells are 
referred to as CD8+ T cells and CD4+ T cells.  CD8+ T cells have the ability to lyse cells 
that are infected or damaged, whereas CD4+ T cells modulate the immune response. A 
subset of CD4+ T cells called T regulatory cells (Treg) have immune suppressive 
	  9 
properties. T regulatory cells are identified by the presence of the forkhead transcription 
factor Foxp3 and the expression of the co-receptors CD4+CD25+. CTLA-4 plays an 
important part in Treg suppression of the immune system in a variety of ways32.  CTLA-4 
on Treg cells transduces a co-stimulatory signal with the TCR to activate other Treg cells to 
increase suppression33,34,35. There is also evidence that CTLA-4 on Treg mediates 
suppression directly by triggering the induction of indolamine 2, 3-dioxygenase, an 
enzyme that catalyzes the conversion of tryptophan to kynurenine, which has 
immunosuppressive effects in the immediate environment. This induction is achieved by 
the binding of CTLA-4 with CD80/CD86 receptor on dendritic cells36,37,. Treg cells also 
constitutively express CTLA-4 unlike their naive T cell counter parts which only express 
CTLA-4 after activation34,35. Mouse models have shown that antibodies directed at the 
CTLA-4 receptor abolish the protective effect that CD25+CD4+ Treg cells provide in 
inflammatory bowel disease model in mice34.  Anti-CTLA-4 antibodies are also used in 
other mouse models to elicit autoimmune diseases similar to those produced by depletion 
of CD25+CD4+ Treg cells without depleting their numbers35. This emphasizes the role of 
CTLA-4 on Treg cells as an important part of the immunosuppressive environment, 
tolerance and ipilimumab-induced colitis. 
With respect to ipilimumab-induced colitis, the disruption of the immune-
suppressive environment of the gut is thought to result in nonspecific and cross-reactive 
tissue damage to the intestines caused by activated T cells. Concurrently, there is some 
evidence that patients with previous autoimmune inflammatory conditions of the bowel 
are more likely to develop ipilimumab induced colitis30. Other biological markers that 
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predict susceptibility to ipilimumab-induced colitis have fallen short and currently no 
established predictive markers exist.  
Patients with suspected ipilimumab-induced colitis often undergo both a CT scan 
of the abdomen/pelvis and a colonoscopy to confirm the diagnosis. Intestinal perforation 
is a rare but serious complication of colonoscopy, but the risk increases in patients with 
ipilimumab induced colitis because of the inflamed tissue (0.5–1%)38,29,6. Radiologic 
findings have not been previously correlated with colonoscopy or biopsy findings for 
ipilimumab induced colitis. Using CT scans alone as a diagnostic tool to identify 
ipilimumab-induced colitis would be preferable given its non-invasive nature compared 
to colonoscopy. The majority of patients with ipilimumab-induced colitis exhibit CT 
findings of mesenteric vessel engorgement (81.3%), and bowel wall thickening (75%). 
Some patients have CT findings of fluid-filled distended colon, suggestive of diarrhea, 
(25%), underlying diverticulosis (25%) and increased mucosal enhancement (18.8%)39. 
Validating the effectiveness of CT scans for diagnosing ipilimumab-induced colitis could 
simultaneously decrease time to diagnosis and reduce the risk of bowel perforation 
associated with colonoscopy.  
Purpose of Study 
The Purpose of this study is to understand the clinical course of patients presenting with 
gastrointestinal symptoms after ipilimumab and to assess the clinical characteristics that 
improve diagnosis of immune related colitis after ipilimumab. 
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Primary Study Question 
Can the clinical characteristics of gender, age, body mass index and the timing, frequency 
and number of doses and symptoms differentiate patients who present with 
gastrointestinal symptoms from those who go on to develop ipilimumab-induced colitis? 
Primary and Secondary Objectives 
Primary Objective 
1) To understand if the clinical characteristics of gender, age, body mass index and the 
timing, frequency and number of doses and symptoms can help differentiate patients who 
present with gastrointestinal symptoms from those who develop ipilimumab-induced 
colitis.  
Secondary Objectives 
2a) To evaluate if CT scans are an effective diagnostic tool for the identification of 
ipilimumab induced colitis, in the setting of finding a low risk diagnostic tool for rapid 
identification of ipilimumab-induced colitis in patients who present with diarrhea and 
associated gastrointestinal symptoms.  
2b) To assess if the clinical characteristics of gender, age, body mass index and the 
timing, frequency and number of doses and symptoms can help identify patients with 
ipilimumab induced colitis who develop bowel perforation.  
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 Study Rationale 
Reports on the clinical course of ipilimumab induced colitis, from presentation of 
symptoms to resolution, have previously been limited to a small number of case studies 
with varying diagnosis and treatment protocols40,41. There have been no previous studies 
comparing CT and colonoscopies as diagnostic tools for ipilimumab-induced colitis.  
Comparative studies between CT and colonoscopy in the general population focus on 
colorectal cancer screening using CT colonography for the identification of pre-cancerous 
adenomas whereas in the detection of ipilimumab-induced colitis a CT of the abdomen 
and pelvis is used42. Of note, the colorectal cancer screening studies are used as 
preventative diagnostic tools where time is not typically a major concern. A more 
relevant, though less direct, comparison was studied in inflammatory bowel disease. 
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative 
colitis (UC), arises from the deregulation of GI mucosal immunity and thus similarities 
between ipilimumab-induced colitis and IBD are of interest43. Diagnosis and assessment 
of IBD was historically achieved via endoscopy however the field has moved towards 
combined PET/CT scans. A 2007 study found that there was a 100% sensitivity for the 
detectability of severe lesions in IBD and 70% sensitivity for the detectability of all 
lesions in IBD with combined PET/CT compared to endoscopy44. Ipilimumab-induced 
gastrointestinal symptoms and adverse events have been thoroughly documented in the 
clinical trials of ipilimumab although the diagnostic workup has not been studied 
systematically. At our institution the majority of patients with suspected immune-related 
colitis were evaluated with both CT scans and colonoscopy/biopsy. This allows for a 
	  13 
well-documented clinical course of patients who have been treated with ipilimumab and 
who experienced irAE’s. We hypothesize that better understanding of the clinical course, 
the validity of our diagnostic tools, and the response to treatment for colitis allows for 
improved diagnosis and treatment of patients with immune-related colitis in the future. 
Methods 
Study Design and Subject Population 
This retrospective cohort study was conducted at Dana Farber Cancer Institute. 
Subjects were identified through the electronic medical record system.  All patients were 
diagnosed with metastatic melanoma and had received at least one dose of ipilimumab on 
an expanded access protocol or as standard of care between the years of 2008 and 2015.  
To be included, patients must have had at lease 1 episode of diarrhea (Table 1). To be 
placed in the category of having developed ipilimumab induced colitis patients must have 
had a diagnostic test confirming ipilimumab induced colitis or received steroid treatment 
for resolution of symptoms.  
Table 1: Inclusion and Exclusion Criteria 
Inclusion Exclusion 
General   
 Patient receiving treatment at Dana Farber 
Cancer Institute and/or Brigham and Women’s 
Hospital 
Received the majority of care at a clinic not 
pertaining to Dana Farber Cancer Institute 
and/or Brigham and Women’s Hospital 
Received at least 1 dose of ipilimumab   
Received care on expanded access protocol or 
as standard of care during 2008–2015 
 
Gastrointestinal Symptoms   
Had at least 1 episode of diarrhea  
Ipilimumab Induced Colitis   
Confirmatory diagnostic test or received steroid 
treatment for resolution of symptoms. 
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Statistical Analysis 
Medical records were reviewed for suspected immune related colitis and the 
method used for diagnosis (CT scan and/or colonoscopy and biopsy). Other information 
extracted from the medical record included demographic data: age and sex, but mostly 
relied on clinical data related to the course of symptoms, treatment and diagnostic tools 
(Table 2). The primary endpoint for the first objective of the study was to identify criteria 
that were different between the group of patients who only had gastrointestinal symptoms 
compared to the group of patients who developed ipilimumab-induced colitis in one or 
more of the categories extracted from the medical record (Table 2). The primary endpoint 
for aim 2b was the same. To test statistical differences between the two groups for aims 1 
and 2b a two-sided Welch T-test with a 95% confidence interval was used for the 
continuous variables in Table 1 and a chi-squared test was used for the categorical 
variables in Table 2.  For gender in aim 2b a chi-squared test with Yates correction was 
used because of the small sample size. These tests were calculated in R along with the 
mean and standard deviation for each variable or N (%) for categorical variables.  
The primary endpoints for objective 2 are to assess the sensitivity, specificity and 
positive and negative likelihood ratios of the CT scans. Two methods were used to 
identify the validity of the CT scan results. Firstly, for those patients who received both a 
CT scan and colonoscopy/biopsy (27 patients), the biopsy results were used to validate 
the CT findings. For those patients who received a CT scan (43) the CT findings were 
validated by their need to receive steroid treatment for resolution of symptoms.  Patients 
were identified as having ipilimumab-induced colitis if they had a confirmation biopsy or 
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needed steroid treatment to manage their symptoms. The analysis for sensitivity, 
specificity, positive and negative predictive value and positive and negative likelihood 
ratio was performed in R.  Sensitivity is the probability of a patient having ipilimumab-
induced colitis and also having positive CT findings. Specificity is the probability of a 
patient who does not have ipilimumab-induced colitis also having a negative CT. The 
positive predictive value (PV+) is the probability of a patient who receives a positive CT 
result actually having ipilimumab-induced colitis and the negative predictive value (PV-) 
is the probability of a patient with a negative CT result not having ipilimumab-induced 
colitis.  Likelihood ratio (LR) tells us how much of an increase or decrease there is in the 
probability of finding ipilimumab-induced colitis when we do not know whether the 
patient has or does not have ipilimumab-induced colitis. There are two types of LR, 
positive likelihood (LR+) and negative likelihood (LR-).  LR+ is the probability of a 
patient having ipilimumab-induced colitis with a positive CT result over the probability 
of a patient who does not have ipilimumab-induced colitis having a positive CT. A large 
LR+, for example between 5 and 10, gives a moderate increase in the likelihood that 
there is presence of ipilimumab-induced colitis if the CT scan is positive. LR – is the 
probability of a patient with ipilimumab-induced colitis having a negative CT results over 
the probability of a patient without ipilimumab-induced colitis having a negative CT 
results.  A very small number in this case (0.1–0.02) gives a moderate increase in the 
likelihood of not having ipilimumab-induced colitis if CT findings are negative.  
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Confounders 
 For objective 1 and 2b, the naturally disproportionate number of men in the study 
could mask clinically relevant gender differences because of the small sample size of 
women. Previous chemotherapies of patients were not recorded and could potentially 
factor into clinical characteristics analysis, especially if they were on chemotherapies or 
radiation, which could affect their immune system.   
For objective 2a, the prevalence and administration of diagnostic tools could be 
confounding.  Colonoscopies and CT scans are administered at the physician’s discretion 
when the patient presents with severe enough gastrointestinal symptoms to be suspect of 
ipilimumab-induced colitis. Therefore, sicker patients may receive more diagnostic 
evaluation skewing the data to show an increase in the ability for the diagnostic tool to 
detect disease.  
 Results 
  
	  
Table 2: Prevalence of gastrointestinal symptoms, ipilimumab 
induced colitis and the number of patients who received CT scans 
and or colonoscopies. 
Subgroup Patients 
 No. (%) 
     Received ipilimumab 303 (100) 
     Gastrointestinal symptoms 100 (33.00) 
     Ipilimumab induced colitis 46 (15.18) 
     Steroid treatment for colitis   43 (14.19) 
     Bowel Perforation  5(1.65)  
Diagnostic Tools Used  
     CT 43 (44.33) 
     Colonoscopy 47 (48.45) 
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Of the 303 patients who received ipilimumab 33% reported diarrhea and 15.18% 
developed ipilimumab-induced colitis (Table 2).  In both the diarrhea only group and 
ipilimumab induced colitis group there were fewer women 20 (37%), and 15 (32.6%), 
respectively, compared to men 34 (63%) and 31 (67.4%), respectively (Table 3). There 
was no difference in the occurrence of gastrointestinal symptoms or developing 
ipilimumab induced colitis based on gender (Table 3).   
Table 3: Demographic and clinical patient characteristic analysis.   
        
Ipilimumab-
induced Colitis 
Gastrointestinal 
Symptoms p-value 
Mean (SD) Mean (SD)   
Subgroup     
n 46 54   
Gender, n (%)     
     Male  31 (48%) 34 (52%)  
    Female 15 (43%) 20 (57%)  
    
   0.64 
Age 65.14 (±13) 58.13 (±13.4) 0.01 
BMI 28.4 (±4.9) 28.8 (± 5.9) 0.51 
LDH 244.9 (±203) 275 (± 254) 0.24 
Number of doses before onset of 
symptoms 
3 (±1.4) 2.5 (±1.2) 
0.042 
Days to onset of symptoms from 
first dose of  ipilimumab 
53.8 (±35) 71.3 (±78) 
0.13 
Days to resolution of symptoms  37.7 (±29) 6.2 (±7.9) 1.23x10-8 
Days  before onset of symptoms 
per doses of ipilimumab 
 
17.9(± 9.1) 
 
24.7  (±21.2) 0.04 
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Table 4: Bowel perforation in patients with ipilimumab-induced colitis.   
  
Bowel 
Perforation + 
 
Bowel 
Perforation - 
 
 
p-value 
Subgroup    
n 5 46  
Gender, n (%)    
     Male  3 (9%) 31 (91%)  
    Female 2 (12%) 15 (88%)  
   0.87 
Age 72.8 63.3 0.013 
BMI 30.2 28.4 0.44ns 
LDH 172 250 0.089ns 
Number of doses before onset of symptoms 2.6 3.5 0.11ns  
Days to onset of symptoms from first dose of 
ipilimumab 
48.6 65.6 0.307ns 
Days to onset of symptoms per doses of 
ipilimumab 
 
17.6(± 9.8) 
 
19.2  (±3.11) 
0.4601ns 
Colonoscopy, n (%)  5 (100%) 44 (95%) 6.0x10-8 
        
Patients who developed ipilimumab-induced colitis were older (65.14, ±13) 
compared to patients who reported diarrhea (58.13, ±13.4) (p= 0.01289). BMI and LDH 
were not different between the two groups (BMI: 28.4, ±4.9 and 28.8, ± 5.9; LDH: 244.9, 
±203 and 275, ± 254) (Table 3). Patients who developed ipilimumab-induced colitis had 
significantly more doses of ipilimumab (3.1, ± 1.4) than did patients with diarrhea, but 
not colitis (2.5, ± 1.2, p= 0.04162). Patients who developed ipilimumab-induced colitis 
did not have a statistically significant difference between time of onset of symptoms after 
the first dose of ipilimumab (53.8 ± 35) than did those who only developed diarrhea (71.3 
±78, p=.1247). Patients with ipilimumab-induced colitis had significantly longer time to 
resolution of symptoms than patients with diarrhea only (37.7, ±29 and 6.2, ± 7.9, 
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respectively p=1.225x10-8) (Table 3).  The frequency of days per dose of ipilimumab was 
shorter for patients who developed ipilimumab-induced colitis than for those who only 
developed gastrointestinal symptoms (17.9 (± 9.1) and 24.7 (±21.2) p= 0.0387, 
respectively) (Table 3). 
 Bowel perforation was an uncommon complication of ipilimumab-induced colitis 
with a prevalence of 1.65% and only occurred in patients who also received a 
colonoscopy. Patients with bowel perforation were significantly older (72, ±5.45, = 5) 
compared with those who did not have a bowel perforation (64.2 ±13.61, = 41) with a p-
value of less than 0.05 (p= 0.01257) (Table 4).  
Of the patients who were treated with ipilimumab and developed symptoms 
typical of ipilimumab induced colitis 43 and 47 had symptoms severe enough to result in 
a CT scan or a colonoscopy with biopsy, respectively (Table 2).  Common findings from 
the CT include bowel wall thickening (55%) and air or fluid filled bowel indicative of 
diarrhea (23%) (Table 5). Only 3% of the patients who were diagnosed with colitis did 
not have defined findings on their CT scans. 
Table 5: Sensitivity and specificity analysis of CT scans by biopsy and treatment with 
steroids. 
  
Biopsy 
Steroid 
Treatment 
Subgroup No. (%) No. (%) 
N 31 44 
Sensitivity  85.19% 85.19% 
Specificity 75.00% 88.24% 
Positive Predictive Value 95.83% 92.00% 
Negative Predictive Value 42.86% 78.95% 
Positive Likelihood Ration (LR+)  3.3 7.2 
Negative Likelihood Ratio (LR-) .19 .16 
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The diagnostic performance of the CT scan was validated using two methods. All 
patients who received a colonoscopy also underwent a colon biopsy. Therefore, of the 31 
patients who received both diagnostic tools (CT and Colonoscopy) the CT findings were 
compared to the biopsy results from the colonoscopy (Table 5: Biopsy group).  The 
sensitivity and specificity of CT to detect colitis was 85 and 75%, respectively.  
The positive and negative predictive value of the CT was 95.8 and 42.9,% 
respectively. The negative likelihood ratio showed a moderate increase in the probability 
of ruling out disease (0.19) and the positive likelihood ratio showed a small increase in 
the probability of ruling in disease (3.3)45. 
  The second approach to validate the use of CT for the diagnosis of immune-
related colitis was to correlate the CT results with the use of steroids to achieve resolution 
of colitis symptoms (Table 5, Treatment group).  With this approach, the sensitivity and 
specificity of CT was of 85.2 and 88.2%, respectively. The positive and negative 
predictive value of the CT was 92 and 79%, respectively. The negative likelihood ratio 
showed a moderate increase in the probability of ruling out disease (0.16) and the 
positive likelihood ratio also showed a moderate increase in the probability of ruling in 
disease (7.2)45. 
Discussion 
Colitis can be a life-threatening immune-related adverse event (irAE) for patients 
treated with immune checkpoint blockade. With the increased use of immune checkpoint 
blockade, particularly the combination of anti-CTLA-4 and PD-1 inhibition in melanoma 
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and other cancers, timely and accurate diagnosis of colitis will become increasingly 
important for oncologists. 
Clinical Presentation and Characteristics of Ipilimumab-Induced Colitis in the 
Clinical Setting 
 Of the 303 patients who received ipilimumab at Dana Farber Cancer Institute, 97 
developed diarrhea and, 46 developed ipilimumab induced colitis, and 43 required 
corticosteroids for resolution of their symptoms (Table 2). The study cohort had more 
men, 67% in the ipilimumab-induced colitis groups and 63% in the group that only had 
symptoms.  There was no difference in the frequencies of diarrhea or ipilimumab-induced 
colitis based on gender (Table 4). The frequencies of diarrhea (33%) and colitis (15%) in  
our cohort were similar to those reported in other studies and were similar in the patients 
treated on expanded access protocol and as standard of care6,26,13,39 (Table 2). Bowel 
perforation was slightly more common (1.65%) in our cohort compared to the 
frequencies reported from clinical trials (0.5–1%) which could reflect a sicker patient 
population28,11 (Table 2). Advanced age seems to be a potential risk factor for the 
development of ipilimumab-induced colitis  (65.14 and 58.13,p=0.01) and bowel 
perforation (72.8 and 63.3, p=0.012)(Tables 4, 5). This could be due to an aging gut: 
some research has shown that both the physiology and the microbiome of the gut change 
with age and may contribute to increased inflammation and immune deregulation46,47. It 
may be interesting to investigate fecal inflammatory markers such as calprotectin, 
lactoferrin, M2-PK and S100A12 from patients before the first dose of ipilimumab and 
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see if there are any elevated markers that correlate to developing ipilimumab-induced 
colitis48. Concurrently, a microbiome panel can be established from patients before the 
start of treatment to see if any specific composition of bacteria can lead to an increased 
risk of developing ipilimumab induced colitis46. The increased risk of bowel perforation 
in older patients highlights the need for non-invasive diagnostic methods. The number of 
days per dose of ipilimumab (or ipilimumab-days) was lower for patients who developed 
ipilimumab-induced colitis than for those who only developed gastrointestinal symptoms 
(17.9 and 24.7, respectively)(Table 3). This indicates that patients who received 
ipilimumab in a shorter time period or had less time between each dose of ipilimumab 
had a greater chance of developing ipilimumab-induced colitis. This could be due to two 
situations: either the dosing scheduling does not allow enough time between doses to 
lower toxicity or it could be that for the ipilimumab-colitis-susceptible patient population 
having more spacing between doses could limit the development of ipilimumab induced 
colitis.  
The clinical course of gastrointestinal symptoms may also help in predicting 
which patients will develop colitis requiring steroids for resolution. Patients who do not 
develop colitis have a significantly shorter course of diarrhea (6 days) compared with 
those who develop colitis (37.6 days) (Table 3). Another noteworthy clinical 
characteristic, of those patients who develop colitis after presenting with diarrhea is that 
they have received significantly more doses of ipilimumab (3.2), than those who have 
diarrhea but do not develop colitis (2.5) (Table 3). Previous studies have shown that there 
is some correlation of ipilimumab-induced toxicity affirming the results seen here. The 
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duration of diarrhea and the number of ipilimumab doses received may help to risk 
stratify patients in a way that can help the clinician decide which patients require further 
diagnostic evaluation.   
CT Findings and Validation 
The most common findings on CT scans in patients with ipilimumab-induced 
colitis were bowel wall thickening (55%) and air or fluid filled bowel (23%) (Table 4). 
This is similar to previously documented CT findings in ipilimumab induced colitis39. 
Bowel wall thickening and air or fluid filled bowel may be characteristics of ipilimumab-
induced colitis. To help increase the accuracy of CT scan findings further, better 
understanding of the CT findings reflecting pathology are desired. A follow-up 
experiment that has potential to yield useful information would be the prospective 
gathering and evaluation of CT scans of a greater number of patients with ipilimumab 
induced colitis and those without to establish precise pathology characteristics of CT-
findings that can help identify ipilimumab-induced colitis.  
 Colonoscopy and CT scans were performed commonly but not universally in 
patients who presented with symptoms suggestive of colitis (Table 5). In the first 
assessment of the predictability of the CT scan, 31 patients were analyzed who had 
received both a CT scan confirmed with colonoscopy and biopsy (Table 5, Biopsy 
group).  The CT could correctly identify 85% of patients who had ipilimumab-induced 
colitis and 75% of patients without colitis. The negative likelihood ratio was small (0.19) 
which means there was a moderate increase in the probability that the test accurately 
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ruled out disease or that the CT scan had a large to moderate ability to identify the 
absence of disease. The positive likelihood ratio was not very large (3.3) and therefore 
there was only a small increase in the probability that the CT scan could correctly 
identify the presence of colitis.  
For the patients who only received a CT scan without colonoscopy and biopsy we 
confirmed the CT results with the need for steroids to achieve resolution of colitis.  The 
second approach to validate the CT results was to correlate the CT results with the use of 
steroids to achieve resolution of colitis symptoms (Table 7, Treatment group).  The CT 
could correctly identify 85% of patients who had ipilimumab-induced colitis and 88% of 
patients without disease. The negative likelihood ratio was small (0.16) which means 
there was a moderate increase in the probability that the test accurately ruled out disease 
or that the CT scan had a large to moderate ability to identify the absence of colitis. The 
positive likelihood ratio was large (7.2) and therefore there was moderate increase in the 
probability that the CT scan could correctly identify the existence of colitis (Table 7). 
Given these findings, we propose that colonoscopy poses an unnecessary risk and may 
not be needed to firmly establish the diagnosis of ipilimumab-induced colitis in the 
presence of diarrhea and CT findings of colitis. 
Limitations 
Fifteen of the 17 patients with negative CT findings did not need steroids to reach 
resolution of symptoms. Not all patients received a CT scan or colonoscopy. Those who 
underwent both procedures may have had more severe symptoms and therefore may have 
been more likely to have positive results on CT or colonoscopy. This could lead to an 
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over exaggeration of the accuracy of CT scan. However, since we assessed all patients 
who developed gastrointestinal symptoms we likely captured the milder cases as well in 
our analysis. Additionally, given the retrospective nature of this evaluation the patients 
who went on to get further diagnostic evaluation are the patients that were deemed 
clinically worrisome to the provider and therefore the patient population for which we 
hope to find a safe and accurate diagnostic tool. Another limitation of this study was that 
no multivariable analysis was performed to identify risk factors for colitis. Therefore, 
potential confounders may be present that were not detected in the general analysis.  A 
multivariable analysis could not be calculated for perforation since the sample size was 
too small (5 events). 
Future Direction 
To minimize confounding in aim 2 of the overexaggeration of the accuracy of CT 
scan because sicker patients may receive more CT scans, a prospective study could be 
initiated where all patients receive a CT scan when they report diarrhea or other 
gastrointestinal symptoms suggestive of colitis. The CT evaluation could then be 
evaluated by the need for steroid therapy to resolve symptoms.  Since all patients would 
be receiving a CT scan, a more accurate assessment of the accuracy of CT scan at 
identifying ipilimumab-induced colitis could be achieved. 
Age has not previously been reported as risk factor for adverse events stemming 
from ipilimumab treatment, however our approach was unique since we looked at the 
difference between gastrointestinal symptoms and development of ipilimumab-induced 
colitis as one group which separates into two. Previous studies have assessed age, but 
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only within the separate groups and found no difference6 The aging gut is known to be 
physiologically different as well as to harbor a different microbiome, which may 
contribute to increased inflammation and immune deregulation46,47.  Several follow up 
experiments could be done; primarily it would be interesting if differences in the 
microbiome would be supported in other patient populations. Several retrospective cohort 
studies could be performed at varying institutions looking at patients who develop 
gastrointestinal symptoms and those who continue on to develop colitis with age being 
the primary endpoint.  To understand the biological mechanisms and also potentially 
elucidate a predictive marker for development of ipilimumab-induced colitis, a 
prospective cohort study could be performed which analyzes fecal samples from patients 
who have gastrointestinal symptoms and compares them to patients who develop-
ipilimumab induced colitis. The endpoints would be inflammatory markers such as 
calprotectin, lactoferrin, M2-PK and S100A12 as well as a microbiome panel analysis to 
look at difference between patient groups 48,46. 
 
Conclusion 
 In conclusion, CT of the abdomen/pelvis is a fast, reliable, and non-invasive mode of 
diagnosing ipilimumab induced immune-related colitis, whereas colonoscopy may not be 
needed to firmly establish that diagnosis. Given these findings, we propose that 
colonoscopy poses an unnecessary risk and may not be needed to firmly establish the 
diagnosis of ipilimumab-induced colitis in the presence of GI symptoms and CT findings 
of colitis.  
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Systematic diagnostic evaluation if immune-related colitis: a single instituting 
review of advanced melanoma patients treated with ipilimumab.  Melina 
Marmarelis*, Marlene Garcia-Neuer*, Jason Luke, Nageatte Ibrahim, Meredith 
Davis, Hilary Donahue, Nancy Bailey, F. Stephen Hodi, Patrick A. Ott. Society 
for Melanoma Research Annual Meeting, November 18th , 2015. *Contributed 
equally.  
AAI Annual Meeting May 2014 
 DNA origami: single cell analysis of T cell receptors without single cell 
sorting. Schoettle, L., Wei, X., Garcia-Neuer, M., Zarnitsyna, V., Antia, R., 
Yan, H., & Blattman, J. (2014). LYM7P. 719). The Journal of Immunology, 192. 
American Association of Immunology Annual Meeting.  
AAAS Annual Meeting February 2014 
“The Public Versus Private Nature of Naïve T Cell Receptor Gene 
Recombination Profiling” Marlene Garcia-Neuer, Louie Schoettle, Philip 
Johnson, Harlan Robins, Rustom Antia, & Joseph Blattman. American 
Association for Advancing Science National Meeting, Chicago, Il, 15th February 
2014.	
Arizona/Nevada Branch ASM  March 2012 
Using Single-Chain TCR Transgenic Mice to Estimate Total TCRab Pairing 
Diversity” Marlene Garcia-Neuer, Philip Johnson, Harlan Robins, Rustom Antia, 
& Joseph Blattman. Local Arizona Nevada Branch of American Society of 
Microbiology Arizona State University, Tempe, AZ 2012. 
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Leadership 
Research Mentor 2013–2014 
Research Mentor, Gamma Delta T Cell Receptor Project, CIDV (Center for 
Infectious Disease and Vaccinology), Biodesign, Arizona State University, 
Tempe, AZ and Hamilton High School, Chandler, AZ  
(ca. 6 hr/wk) Advisor: Dr. Joseph Blattman 
Responsibilities: Helped design, perform, analyze and prepare project for 
presentation at a national science fair competition alongside three high school 
students. 
BIOARTISTRY Mini Lecture Series 2014 
Initiator and Organizer, BIOARTISTRY Mini Lecture Series, Arizona State 
University, Tempe AZ. 2014. 
Description: Hosted faculty talks from both the School of Life Sciences and the 
Herberger School of Art, bringing together faculty and students from both 
disciplines to engage in meaningful discussion about the interface of science and 
art. 
Undergraduate Research Association 2014 
Founding Member, Undergraduate Research Association, Arizona State 
University, Tempe, AZ. 2014  
Goals: Provided a supportive community for undergraduates in research. Aided 
students in finding and continuing research. Organized and managed an 
undergraduate research journal and poster symposium. 
 
ASU Flying Samaritans Club 2013–2014 
Vice President, Arizona State University Flying Samaritan’s Club, Tempe, 
AZ. 2013–2014  
Responsibilities: Coordinated meetings, trips and fundraisers. Directed the 
Medical Spanish Series. Worked with club officers to assess and achieve club 
goals.   
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Honors and Awards 
Travel Grant 2015 
Society for Melanoma Research Travel Grant, awarded from Boston University 
Graduate Medical School. Amount: $250 
SOLUR Research Fellow 2014 
School of Life Science Undergraduate Research Grant, Arizona State 
University, Tempe AZ. Amount: $2,000 
Travel Grant 2014 
AAAS National Conference Travel Grant Award from Barrett the Honors 
College and the Center for Biology and Society. Amount: $1,000  
Scholarship 2010–2014 
Dean’s Award Scholarship, 4 years, Arizona State University, Tempe, AZ. 
Amount: 2,500 per year. 
 
 
